# The value, diagnostic efficacy and clinical significance of functional magnetic resonance imaging in evaluating the efficacy of neoadjuvant chemotherapy in patients with triple negative breast cancer.

> **Reliability concern:** This paper was retracted on 2024-02-21. See notice: 10.3389/fonc.2024.1383383.

- **DOI:** [10.3389/fonc.2023.1132186](https://doi.org/10.3389/fonc.2023.1132186)
- **Rating:** Limited (2.2 out of 5)
- **Verdict:** A small single-centre TNBC imaging study whose material internal inconsistencies in reported diagnostic metrics undermine its modest incremental contribution.
- **Framework version:** v5.0
- **Pipeline version:** v0.4
- **Evaluation date:** 2026-06-01
- **Evaluation page:** https://www.nabu.science/paper/10.3389%2Ffonc.2023.1132186

## Strengths

- **Clinically relevant question with defined population** The study targets a specific clinical need — non-invasive early prediction of NAC response in TNBC — with a clearly defined patient population and a pathological reference standard (Miller-Payne classification).
  - Dimension: contribution
  - Location: Methods section (inclusion criteria, pathological evaluation)
- **Adequate MRI technical specification** The MRI acquisition protocol is described with sufficient technical detail, including scanner model (GE Signa Excite HD 3.0T), coil type, b-value (1000 s/mm²), and sequence parameters (TR, TE, slice thickness), enabling basic methodological assessment.
  - Dimension: methodological rigour
  - Location: Methods section (Instrument and scanning method)
- **Honest limitation acknowledgment and prior work citation** The Discussion cites directly relevant prior studies (Ehsani An, Allard-Coutu A, Siow Z.R) and explicitly acknowledges the need for multicenter, larger-sample validation before clinical application.
  - Dimension: positioning
  - Location: Discussion section (final paragraphs, references 41-44)

## Limitations

- **Material inconsistency in primary diagnostic metrics** The paper's headline ROC results differ between sections: AUC 0.673 (Results) vs. 0.654 (Discussion), sensitivity 71.9% vs. 61.5%, specificity 55.0% vs. 75.0%, and cut-off 1.418 vs. 1.272×10⁻³ mm²/s. These are not rounding differences and prevent determination of the actual findings.
  - Dimension: methodological rigour
  - Location: Abstract/Results section vs. Discussion section
- **Erroneous ethics statement and conduct gaps** The Ethics Statement refers to an 'animal study' approval for a human patient study, the approving body name differs between Methods and Ethics sections, no conflict of interest statement is provided, and the data availability claim is unverifiable.
  - Dimension: methodological rigour
  - Location: Ethics Statement section, Methods section, end matter
- **No confounder control or reliability reporting** The primary ADC comparison between responders and non-responders is unadjusted for tumor stage, chemotherapy regimen, or baseline characteristics. Despite describing a double-blind reading protocol, inter-reader reliability (ICC or kappa) is not reported.
  - Dimension: methodological rigour
  - Location: Methods section (Statistical Analysis), Results section

## Reliability checks

Concerns (4 of 4 checks).

- **Internal coherence:** Concern. The paper's primary diagnostic performance metrics differ substantially between the Abstract/Results and the Discussion, representing a material inconsistency in the core findings that cannot be resolved from the text.
- **Research conduct:** Concern. The Ethics Statement contains a likely template error referring to an 'animal study' in what is clearly a human patient study, and the institutional naming is inconsistent between the Methods and the Ethics Statement. The data availability claim is unverifiable.
- **Reference integrity:** Clean. All 35 cited references resolved to real publications via PubMed, Crossref, or OpenAlex.
  - References not verified automatically are resolved manually within 24 hours.

## Post-publication record

- **Status:** Concern
- **Summary:** This paper was retracted on 2024-02-21. See notice: 10.3389/fonc.2024.1383383.
- **Last checked:** 2026-10-17
